Skip to main content

Table 4 Anthropometric measurements (PP) at different control times (T1 baseline and, T5, T9, T13) in groups treated with PG and O

From: Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity

Variable

Group

T1

T1 - T5

T1 - T9

T1 - T13

Weight (kg)

polyglucosamine

100.9 ± 13.44

3.71 ± 2.67

5.49 ± 2.63#

6.74 ± 3.14#

orlistat

97.9 ± 11.55

2.82 ± 1.42

3.43 ± 1.69

4.78 ± 2.24

BMI (kg/m2)

polyglucosamine

34.6 ± 3.69

1.26 ± 0.88

1.89 ± 0.90#

2.33 ± 1.09*

orlistat

34.7 ± 4.76

1.00 ± 0.54

1.23 ± 0.64

1.71 ± 0.86

WC (cm)

polyglucosamine

113.4 ± 11.13

3.81 ± 3.11

5.96 ± 4.13

8.33 ± 4.42*

orlistat

109.5 ± 10.13

2.61 ± 2.65

5.29 ± 2.47

6.10 ± 3.43

  1. #p<0.01, * p < 0.05
Back to article page

BMC Obesity

ISSN: 2052-9538

Contact us